Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as add-on to Standard of Care in Adult Subjects With COVID-19

NCT04880642 is registered in ClinicalTrials.gov with Vicore Pharma AB as lead sponsor.

NCT NCT04880642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04880642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as add-on to Standard of Care in Adult Subjects With COVID-19
Lead sponsor
Vicore Pharma AB
Phase
Phase 3
Overall status
Completed
Start date
September 16, 2021
Completion date
April 25, 2022
Enrollment
272 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19